Icosavax, Inc.
1616 Eastlake Avenue E., Suite 208
Seattle, WA 98102
July 26, 2021
VIA EDGAR
Mr. Alan Campbell
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Icosavax, Inc. |
Registration Statement on Form S-1
File No. 333-257733
Dear Mr. Campbell
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Icosavax, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 28, 2021, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| ICOSAVAX, INC. | ||
| By: |
/s/ Adam Simpson | |
| Adam Simpson | ||
| Chief Executive Director | ||
cc:
Suzanne Hayes, Securities and Exchange Commission
Julie Sherman, Securities and Exchange Commission
Brian Casio, Securities and Exchange Commission
Thomas Russo, CFA, Icosavax, Inc.
Cheston J. Larson, Latham & Watkins LLP
Matthew T. Bush, Latham & Watkins LLP
Alaina P. Ellis, Latham & Watkins LLP